Published on 24 Feb 2022 on Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced that its board has appointed David Hering as interim chief executive officer, effective immediately. Hering's appointment came following the resignation of Tillman Gerngross as CEO. The interim CEO will retain his role as chief operating officer.
NASDAQ.VIR price evolution
NASDAQ.MMSI price evolution
NASDAQ.MGNX price evolution
NASDAQ.GTHX price evolution
NASDAQ.LMAT price evolution
NASDAQ.IOVA price evolution
NASDAQ.LUNG price evolution
NASDAQ.DTIL price evolution
NASDAQ.EDIT price evolution
NASDAQ.PCRX price evolution
NASDAQ.NTRA price evolution
NASDAQ.PLSE price evolution
NASDAQ.FOLD price evolution
NASDAQ.OPK price evolution
NASDAQ.SGMO price evolution
NYSE.NVTA price evolution
NASDAQ.BMRN price evolution
NASDAQ.ICUI price evolution
NASDAQ.ABCL price evolution
NASDAQ.CDNA price evolution
NASDAQ.CDXS price evolution
NASDAQ.AGIO price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free